{rfName}
Co

Indexed in

License and Use

Icono OpenAccess

Citations

Altmetrics

Analysis of institutional authors

Lopez-Sendon Hentschel, Jose LuisAuthor

Share

September 13, 2024
Publications
>
Article
Sí

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Publicated to: Clinical Research in Cardiology. 111 (5): 560-573 - 2022-05-01 111(5), DOI: 10.1007/s00392-022-01996-2

Authors:

Lip GYH; Kotalczyk A; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Marler S; Gurusamy VK; Huisman MV; Abban DW; Aziz E; Kalan MB; Abdul N; Backes LM; Bradman D; Abud AM; Badings E; Brautigam D; Adams F; Bagni E; Breton N; Addala S; Baker SH; Brouwers PJAM; Adragão P; Bala R; Browne K; Ageno W; Baldi A; Cortada JB; Aggarwal R; Bando S; Bruni A; Agosti S; Banerjee S; Brunschwig C; Agostoni P; Bank A; Buathier H; Aguilar F; Esquivias GB; Buhl A; Linares JA; Barr C; Bullinga J; Aguinaga L; Bartlett M; Cabrera JW; Ahmed J; Basic Kes V; Caccavo A; Aiello A; Baula G; Cai S; Ainsworth P; Behrens S; Caine S; Aiub JR; Bell A; Calò L; Al-Dallow R; Benedetti R; Calvi V; Alderson L; Mazuecos JB; Sánchez MC; Velasco JAA; Benhalima B; Candeias R; Alexopoulos D; Bergler-Klein J; Capuano V; Manterola FA; Berneau JB; Capucci A; Aliyar P; Bernstein RA; Caputo R; Alonso D; Berrospi P; Rizo TC; da Costa FAA; Berti S; Cardona F; Amado J; Berz A; da Costa Darrieux FC; Amara W; Best E; Vera YCD; Amelot M; Bettencourt P; Carolei A; Amjadi N; Betzu R; Carreño S; Ammirati F; Bhagwat R
[+]

Affiliations

Beijing Anzhen Hospital, Capital Medical University - Author
Boehringer Ingelheim International GmbH - Author
Boehringer Ingelheim Pharmaceuticals, Inc. - Author
Clinica y Maternidad Suizo Argentina - Author
Leids Universitair Medisch Centrum - Author
Liverpool Heart and Chest Hospital; Slaski Uniwersytet Medyczny w Katowicach - Author
Liverpool Heart and Chest Hospital; Slaski Uniwersytet Medyczny w Katowicach; Aalborg University - Author
RTI Health Solutions - Author
The Mount Sinai Medical Center - Author
Universitat Duisburg-Essen - Author
See more

Abstract

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013. Graphical abstract: [Figure not available: see fulltext.]
[+]

Keywords

ApixabanAtrial fibrillationDabigatranNon-vitamin k antagonistsRivaroxaban

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical Research in Cardiology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous). Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 1.93, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-05, the following number of citations:

  • Scopus: 17
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 38.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 38 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 5.
  • The number of mentions on the social network X (formerly Twitter): 8 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Argentina; China; Denmark; Germany; Netherlands; Poland; United Kingdom; United States of America.

[+]